

---

## Author Index for Volume 15

---

Abrams K, 349  
AGIS Investigators, 299  
Ambrosioni E, 201  
Ashby D, 349  
Azen SP, 489  
Bailey KR, 15  
Barros F, 379  
Battistutta D, 512  
Belizan J, 379  
Berry DA, 360  
Bhopal R, 331  
Blackburn GH, 284  
Borenstein M, 411  
Borghici C, 201  
Bradley EJ, 284  
Brooks MM, 437  
Buist AS, 154  
Caggiula AW, 44  
Campion J, 437  
CAST Investigators, 437  
CHART Steering Committee, 482  
Chen S, 277  
Chen TT, 124  
Chuang-Stein C, 30  
Comstock GW, 247  
Connor RJ, 81  
Cook NR, 173  
Cook RJ, 187  
Cowan CD, 24  
Davis CE, 11, 294  
Day SJ, 328  
Dianzumba S, 395  
Doyle SR, 100  
Durham K, 512  
Errington D, 349  
Everett V, 482  
Farnot U, 379  
Fisher LD, 450  
Fisher S, 244  
Fletcher BJ, 59  
Fletcher GF, 59  
Frost C, 512  
Gaffney P, 512  
Galai N, 165  
Gibson D, 482  
Gillis BP, 44  
Gooley TA, 450  
Gordon I, 77  
Gorkin L, 437  
Grandits GA, 395  
Green A, 512  
Greenberg RP, 244  
Greer AL, 432  
Hart V, 512  
Harvey AJ, 482  
Henzlova MJ, 284  
Hertert S, 154  
Hillis A, 523  
Hirst L, 512  
Howel D, 331  
Jensen BE, 59  
Jones FL, 44  
Jones MP, 135  
Katz J, 220  
Kerwin A, 1  
Kirby AJ, 165  
Krol WF, 335  
Lang C, 512  
Langer A, 379  
Latin American Network for Perinatal and Reproductive Research (LANPER), 379  
LeClerq SC, 220  
Ledingham RB, 437  
Lee JV, 59  
Leslie D, 512  
Liebson PR, 395  
Magnani B, 201  
Marks G, 512  
Martin PJ, 450  
Maurer E, 44  
Meehan RM, 44  
Meinert CL, 235  
Modification of Diet in Renal Disease Study, 44  
Moher D, 503  
Moser HW, 161  
Muñoz A, 165  
Nambour Prevention Study Group, 512  
Nanda NC, 59  
Oberman A, 59  
O'Gorman TW, 135  
Orrell E, 512  
Osborne ML, 154  
OSTR Collaborative Group, 503  
Overall JE, 100  
Parmer MKB, 482  
Parsons P, 512  
Pettinger M, 450  
Pradhan EK, 220  
Prineas RJ, 395  
Prorok PC, 81  
Raczynski BJ, 59  
Rogers WJ, 284  
Rosner BA, 173  
Rubins HB, 7  
Sack D, 360  
Sather HN, 489  
Schron EB, 437  
Simon R, 463  
Simon RM, 124  
SMILE Study Investigators, 201  
SOLVD Close-Out Working Group, 284  
Soong S-j, 277  
Spechler SJ, 335  
Thall PF, 463  
VA Cooperative Study Group on Gastroesophageal Reflux Disease (GERD), 335  
Victoria CG, 379  
Villar J, 379  
Vollmer WM, 154  
Watson R, 77  
West KP, Jr, 220

Wheeler RH, 277  
Wiklund I, 437  
Willan AR, 211  
Williams DH, 294  
Williams G, 512

Williford WO, 335  
Witte CL, 1  
Witte MH, 1  
Wittes J, 5, 24  
Wolff MC, 360

Woolson RF, 135  
Xiang AH, 489  
Yamamoto ME, 44

---

# Subject Index for Volume 15

---

**ACE INHIBITOR**

Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study: Rationale, Design, Organization, and Outcome Definitions, 201

**ANALYSIS OF COVARIANCE**

Estimating Sample Sizes for Repeated Measurement Designs, 100

**ANALYSIS OF VARIANCE**

Estimating Sample Sizes for Repeated Measurement Designs, 100

**ASSIGNMENT METHODS**

Reporting of Assignment Methods in Clinical Trials, 294

**AUTOCORRELATION**

Sample Size Estimation Using Repeated Measurements on Biomarkers as Outcomes, 165

**BASAL CELL CARCINOMA**

The Nambour Skin Cancer and Actinic Eye Disease Prevention Trial: Design and Baseline Characteristics of Participants, 512

**BASELINE CORRECTION**

Estimating Sample Sizes for Repeated Measurement Designs, 100

**BAYESIAN INFERENCE**

A Bayesian Approach to Establishing Sample Size and Monitoring Criteria for Phase II Clinical Trials, 463

Simple Bayesian Analysis in Clinical Trials: A Tutorial, 349

**BCG VACCINE**

Field Trials of Tuberculosis Vaccines: How Could We Have Done Them Better?, 247

**BIOLOGICAL MARKERS**

Sample Size Estimation Using Repeated Measurements on Biomarkers as Outcomes, 165

**BIVARIATE RESPONSES**

Interim Monitoring of Bivariate Responses Using Repeated Confidence Intervals, 187

**BLOOD PRESSURE MEASUREMENT**

Clinically Relevant Measures?, 328  
An Optimal Rule for Screening Subjects for Clinical Trials in the Presence of Within-Person Variability, 173

**BONE MARROW****TRANSPLANTATION**

Simulation as a Design Tool for Phase I/II Clinical Trials: An Example from Bone Marrow Transplantation, 450

**BUBBLE SORTING**

Extension of One-Sided Test to Multiple Treatment Trials, 124

**CANCER CHEMOTHERAPY**

A Bayesian Approach to Establishing Sample Size and Monitoring Criteria for Phase II Clinical Trials, 463

**CANCER SCREENING**

Issues in the Mortality Analysis of Randomized Controlled Trials of Cancer Screening, 81

**CARDIAC REHABILITATION**

Design of the Training Levels Comparison Trial, 59

**CATARACT**

The Nambour Skin Cancer and Actinic Eye Disease Prevention Trial: Design and Baseline Characteristics of Participants, 512

**CAUSALITY**

Suspended Judgment: Assessing Cause and Effect from Trials: A Cautionary Note, 331

**CHART**

Is Double Data Entry Necessary? The CHART Trials, 482

**CHOLESTEROL LOWERING**

From Clinical Trials to Clinical Practice:  
Generalizing from Participant to  
Patient, 7  
Generalizing from Clinical Trials, 11

**CLINICAL PRACTICE**

Introduction: From Clinical Trials to  
Clinical Practice[m]Four Papers  
from a Plenary Session, 5

**CLINICAL TRIAL(S)**

Design of the Training Levels Comparison  
Trial, 59

Echocardiography in Multicenter Clinical  
Trials: Experience from the  
Treatment of Mild Hypertension  
Study, 395

Features of the Nutrient Database and  
Analysis System for the  
Modification of Diet in Renal  
Disease Study, 44

Field Trials of Tuberculosis Vaccines: How  
Could We Have Done Them Better?,  
247

Introduction: From Clinical Trials to  
Clinical Practice[m]Four Papers  
from a Plenary Session, 5

Is Double Data Entry Necessary? The  
CHART Trials, 482

An Optimal Rule for Screening Subjects  
for Clinical Trials in the Presence of  
Within-Person Variability, 173

Recruiting Hard-to-Reach Subjects: Is It  
Worth the Effort?, 154

Reporting of Assignment Methods in  
Clinical Trials, 294

Simulation as a Design Tool for Phase I/II  
Clinical Trials: An Example from  
Bone Marrow Transplantation, 450

Survival of Myocardial Infarction Long-  
Term Evaluation (SMILE) Study:  
Rationale, Design, Organization,  
and Outcome Definitions, 201

Suspended Judgment: Reactions to the  
Motion Picture 'Lorenzo's Oil,' 161

**CLINICAL TRIAL DESIGN**

The Advanced Glaucoma Intervention  
Study (AGIS): 1. Study Design and  
Methods and Baseline  
Characteristics of Study Patients,  
299

A Bayesian Approach to Establishing  
Sample Size and Monitoring  
Criteria for Phase II Clinical Trials,  
463

The Nambour Skin Cancer and Actinic

Eye Disease Prevention Trial:  
Design and Baseline Characteristics  
of Participants, 512

Simulation as a Design Tool for Phase I/II  
Clinical Trials: An Example from  
Bone Marrow Transplantation, 450

Survival of Myocardial Infarction Long-  
Term Evaluation (SMILE) Study:  
Rationale, Design, Organization,  
and Outcome Definitions, 201

**CLINICAL TRIAL METHODOLOGY**

From Clinical Trials to Clinical Practice:  
Generalizing from Participant to  
Patient, 7

Generalizing from Clinical Trials, 11

Intercept Studies, Clinical Trials, and  
Cluster Experiments: To Whom Can  
We Extrapolate?, 24

**CLOSE-OUT QUESTIONNAIRE**

Patient Perception of a Long-term Clinical  
Trial: Experience Using a Close-out  
Questionnaire in the Studies of Left  
Ventricular Dysfunction (SOLVD)  
Trial, 284

**COMMUNITY-BASED TRIALS**

Data Management for Large Community  
Trials in Nepal, 220

**COMPLIANCE**

Recruiting Hard-to-Reach Subjects: Is It  
Worth the Effort?, 154

**COMPUTING**

Data Management for Large Community  
Trials in Nepal, 220

**CONFIDENCE INTERVALS**

The Case for Confidence Intervals in  
Controlled Clinical Trials, 411

Interim Monitoring of Bivariate Responses  
Using Repeated Confidence  
Intervals, 187

**CONFIDENCE LIMITS**

The Case for Confidence Intervals in  
Controlled Clinical Trials, 411

**CONSOLIDATED SAFETY DATA**

A New Proposal for Benefit-Less-Risk  
Analysis in Clinical Trials, 30

**CONTINUOUS MONITORING**

A Bayesian Approach to Establishing  
Sample Size and Monitoring

Criteria for Phase II Clinical Trials, 463

**CONTROLLED CLINICAL TRIALS**  
The Case for Confidence Intervals in Controlled Clinical Trials, 411

**COST EFFECTIVENESS**  
An Optimal Rule for Screening Subjects for Clinical Trials in the Presence of Within-Person Variability, 173

**DATA MANAGEMENT**  
Data Management for Large Community Trials in Nepal, 220

**DATA PROCESSING**  
Data Management for Large Community Trials in Nepal, 220

**DECISION MAKING**  
Decision Making during a Phase III Randomized Controlled Trial, 360

**DIET**  
Features of the Nutrient Database and Analysis System for the Modification of Diet in Renal Disease Study, 44

**DIETARY ANALYSIS**  
Features of the Nutrient Database and Analysis System for the Modification of Diet in Renal Disease Study, 44

**DIFFERENCE SCORES**  
Estimating Sample Sizes for Repeated Measurement Designs, 100

**DISCOUNTING PROCEDURE**  
A New Proposal for Benefit-Less-Risk Analysis in Clinical Trials, 30

**DISCOVERY IN MEDICINE**  
Suspended Judgment: Ignorance and the Process of Learning and Discovery in Medicine, 1

**DOUBLE DATA ENTRY**  
Is Double Data Entry Necessary? The CHART Trials, 482

**DOUBLE-MASKED DESIGN**  
Suspended Judgement: Seeing Through the Double-Masked Design: A Commentary, 244

**DRUG TRIALS**  
Suspended Judgement: Seeing Through the Double-Masked Design: A Commentary, 244

**EARLY STOPPING**  
An Efficient Multiple-Stage Procedure for Phase II Clinical Trials that Have High Response Rate Objectives, 277

**ECHOCARDIOGRAPHY**  
Echocardiography in Multicenter Clinical Trials: Experience from the Treatment of Mild Hypertension Study, 395

**EDITORIALS**  
Farewell Swan Song (editorial), 235

**EFFECT SIZE**  
The Case for Confidence Intervals in Controlled Clinical Trials, 411

**EFFICACY**  
Interim Monitoring of Bivariate Responses Using Repeated Confidence Intervals, 187

**EQUIVALENCE TRIALS**  
Interim Monitoring of Bivariate Responses Using Repeated Confidence Intervals, 187

**ERRATA, 326**

**EXERCISE**  
Design of the Training Levels Comparison Trial, 59

**FACTORIAL DESIGN**  
Power Considerations for Testing an Interaction in a  $2 \times k$  Factorial Design with a Failure Time Outcome, 489

**FAILURE TIME**  
Power Considerations for Testing an Interaction in a  $2 \times k$  Factorial Design with a Failure Time Outcome, 489

**GASTROESOPHAGEAL REFLUX DISEASE**  
Development for and Results of the Use of a Gastroesophageal Reflux Disease Activity Index as an Outcome Variable in a Clinical Trial, 335

**GEHAN'S TWO-STAGE PROCEDURE**  
An Efficient Multiple-Stage Procedure for Phase II Clinical Trials that Have High Response Rate Objectives, 277

**GENERALIZATION**  
From Clinical Trials to Clinical Practice: Generalizing from Participant to Patient, 7  
Generalizing from Clinical Trials, 11  
Generalizing the Results of Randomized Clinical Trials, 15  
Intercept Studies, Clinical Trials, and Cluster Experiments: To Whom Can We Extrapolate?, 24

**GLAUCOMA**  
The Advanced Glaucoma Intervention Study (AGIS): 1. Study Design and Methods and Baseline Characteristics of Study Patients, 299

**GROUP SEQUENTIAL DESIGN**  
Interim Monitoring of Bivariate Responses Using Repeated Confidence Intervals, 187

**HETEROGENEITY**  
Generalizing the Results of Randomized Clinical Trials, 15

**HIV-1**  
Sample Size Estimation Using Repeated Measurements on Biomarkers as Outcomes, 165

**HYPERTENSION**  
Echocardiography in Multicenter Clinical Trials: Experience from the Treatment of Mild Hypertension Study, 395

**HYPOTHESIS TESTING**  
The Case for Confidence Intervals in Controlled Clinical Trials, 411  
Generalizing the Results of Randomized Clinical Trials, 15

**INTERACTION**  
Power Considerations for Testing an Interaction in a  $2 \times k$  Factorial Design with a Failure Time Outcome, 489

**INTERCEPT STUDIES**  
Intercept Studies, Clinical Trials, and Cluster Experiments: To Whom Can We Extrapolate?, 24

**LASER SURGERY**  
The Advanced Glaucoma Intervention Study (AGIS): 1. Study Design and Methods and Baseline Characteristics of Study Patients, 299

**LEARNING**  
Suspended Judgment: Ignorance and the Process of Learning and Discovery in Medicine, 1

**LEFT VENTRICULAR DYSFUNCTION (SOLVD)**  
Patient Perception of a Long-term Clinical Trial: Experience Using a Close-out Questionnaire in the Studies of Left Ventricular Dysfunction (SOLVD) Trial, 284

**LETTERS TO THE EDITOR, 523**  
A Note on Sample Size Determination for Comparison of Small Probabilities, 77

**LINEAR TREND TESTS**  
Estimating Sample Sizes for Repeated Measurement Designs, 100

**LONG-TERM CLINICAL TRIAL**  
Patient Perception of a Long-term Clinical Trial: Experience Using a Close-out Questionnaire in the Studies of Left Ventricular Dysfunction (SOLVD) Trial, 284

**LONGITUDINAL STUDIES**  
Sample Size Estimation Using Repeated Measurements on Biomarkers as Outcomes, 165

**'LORENZO'S OIL'**  
Suspended Judgment: Reactions to the Motion Picture 'Lorenzo's Oil,' 161

**MANAGEMENT TRIALS**  
Power Function Arguments in Support of an Alternative Approach for Analyzing Management Trials, 211

**MANTEL-HAENSZEL ESTIMATOR**  
A Comparison of Two Methods of Estimating a Common Risk Difference in a Stratified Analysis of a Multicenter Clinical Trial, 135

**MEDICAL PRACTICE**  
Scientific Knowledge and Social Consensus, 432

**METHODOLOGY**  
Recruiting Hard-to-Reach Subjects: Is It Worth the Effort?, 154

**MORICIZINE**  
Moricizine and Quality of Life in the Cardiac Arrhythmia Suppression Trial II (CAST II), 437

**MORTALITY ANALYSIS**  
Issues in the Mortality Analysis of Randomized Controlled Trials of Cancer Screening, 81

**MULTICENTER TRIAL**  
The Latin American Multicenter Trial on Psychosocial Support During Pregnancy: Methodology and Baseline Comparability, 379

**MULTIPLE 2 x 2 TABLES**  
A Comparison of Two Methods of Estimating a Common Risk Difference in a Stratified Analysis of a Multicenter Clinical Trial, 135

**MULTIPLE COMPARISON**  
Extension of One-Sided Test to Multiple Treatment Trials, 124

**MULTIPLE LINEAR REGRESSION**  
Development for and Results of the Use of a Gastroesophageal Reflux Disease Activity Index as an Outcome Variable in a Clinical Trial, 335

**MULTIPLE STEP**  
Extension of One-Sided Test to Multiple Treatment Trials, 124

**MYOCARDIAL INFARCTION**  
Moricizine and Quality of Life in the Cardiac Arrhythmia Suppression Trial II (CAST II), 437

Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study: Rationale, Design, Organization, and Outcome Definitions, 201

**NEPAL**  
Data Management for Large Community Trials in Nepal, 220

**NEUTRON THERAPY**  
Simple Bayesian Analysis in Clinical Trials: A Tutorial, 349

**NON-NULL HYPOTHESIS**  
Power Function Arguments in Support of an Alternative Approach for Analyzing Management Trials, 211

**NUTRIENT CALCULATION**  
Features of the Nutrient Database and Analysis System for the Modification of Diet in Renal Disease Study, 44

**NUTRIENT DATABASE**  
Features of the Nutrient Database and Analysis System for the Modification of Diet in Renal Disease Study, 44

**ODDS RATIO**  
Simple Bayesian Analysis in Clinical Trials: A Tutorial, 349

**ONE-SIDED TEST**  
Extension of One-Sided Test to Multiple Treatment Trials, 124

**OPEN-ANGLE GLAUCOMA**  
The Advanced Glaucoma Intervention Study (AGIS): 1. Study Design and Methods and Baseline Characteristics of Study Patients, 299

**OUTCOME VARIABLE**  
Development for and Results of the Use of a Gastroesophageal Reflux Disease Activity Index as an Outcome Variable in a Clinical Trial, 335

**PLENARY SESSION**  
Introduction: From Clinical Trials to Clinical Practice[m]Four Papers from a Plenary Session, 5

**POWER**  
Estimating Sample Sizes for Repeated Measurement Designs, 100

Power Considerations for Testing an Interaction in a  $2 \times k$  Factorial Design with a Failure Time Outcome, 489

**POWER FUNCTION**  
Power Function Arguments in Support of an Alternative Approach for Analyzing Management Trials, 211

**PROBABILITIES**

A Note on Sample Size Determination for Comparison of Small Probabilities (letter), 77

**PROPORTIONALITY CONSTANT**

A New Proposal for Benefit-Less-Risk Analysis in Clinical Trials, 30

**PSYCHOTROPIC DRUGS**

Suspended Judgement: Seeing Through the Double-Masked Design: A Commentary, 244

**QUALITATIVE INTERACTION**

Generalizing the Results of Randomized Clinical Trials, 15

**QUALITY OF LIFE**

Moricizine and Quality of Life in the Cardiac Arrhythmia Suppression Trial II (CAST II), 437

**QUERIES**

Clinically Relevant Measures?, 328

**RANDOMIZATION**

Reporting of Assignment Methods in Clinical Trials, 294

**RANDOMIZED CLINICAL TRIALS**

Generalizing the Results of Randomized Clinical Trials, 15

Is Double Data Entry Necessary? The CHART Trials, 482

Moricizine and Quality of Life in the Cardiac Arrhythmia Suppression Trial II (CAST II), 437

**RANDOMIZED CONTROLLED TRIALS**

Decision Making during a Phase III Randomized Controlled Trial, 360

Issues in the Mortality Analysis of Randomized Controlled Trials of Cancer Screening, 81

The Latin American Multicenter

Trial on Psychosocial Support During Pregnancy: Methodology and Baseline Comparability, 379

The Ottawa Stroke Trials Registry Collaborative Group and the Development of the Ottawa Stroke Trials Registry (OSTR),

**RECRUITMENT**

Recruiting Hard-to-Reach Subjects: Is It Worth the Effort?, 154

**REJECTION ERROR**

An Efficient Multiple-Stage Procedure for Phase II Clinical Trials that Have High Response Rate Objectives, 277

**RENAL DISEASE**

Features of the Nutrient Database and Analysis System for the Modification of Diet in Renal Disease Study, 44

**REPEATED CONFIDENCE INTERVALS**

Interim Monitoring of Bivariate Responses Using Repeated Confidence Intervals, 187

**REPEATED MEASUREMENTS**

Development for and Results of the Use of a Gastroesophageal Reflux Disease Activity Index as an Outcome Variable in a Clinical Trial, 335

Estimating Sample Sizes for Repeated Measurement Designs, 100

**RESPONSE RATE**

An Efficient Multiple-Stage Procedure for Phase II Clinical Trials that Have High Response Rate Objectives, 277

**RISK-ADJUSTED BENEFIT**

A New Proposal for Benefit-Less-Risk Analysis in Clinical Trials, 30

**SAFETY PROFILE**

A New Proposal for Benefit-Less-Risk Analysis in Clinical Trials, 30

**SAMPLE SIZE**

The Case for Confidence Intervals in Controlled Clinical Trials, 411

Estimating Sample Sizes for Repeated Measurement Designs, 100

Extension of One-Sided Test to Multiple Treatment Trials, 124

A Note on Sample Size Determination for Comparison of Small Probabilities (letter), 77

Power Considerations for Testing an Interaction in a  $2 \times k$  Factorial Design with a Failure Time Outcome, 489

Sample Size Estimation Using Repeated Measurements on Biomarkers as Outcomes, 165

**SCIENTIFIC KNOWLEDGE**

Scientific Knowledge and Social Consensus, 432

**SCREENING**  
An Optimal Rule for Screening Subjects for Clinical Trials in the Presence of Within-Person Variability, 173

**SELECTION**  
Extension of One-Sided Test to Multiple Treatment Trials, 124

**SEQUENTIAL DESIGN**  
An Efficient Multiple-Stage Procedure for Phase II Clinical Trials that Have High Response Rate Objectives, 277

**SIGNIFICANCE TEST**  
The Case for Confidence Intervals in Controlled Clinical Trials, 411

**SMILE TRIAL**  
Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study: Rationale, Design, Organization, and Outcome Definitions, 201

**SOCIAL CONSENSUS**  
Scientific Knowledge and Social Consensus, 432

**SOCIAL SUPPORT**  
The Latin American Multicenter Trial on Psychosocial Support During Pregnancy: Methodology and Baseline Comparability, 379

**STATISTICAL PRECISION**  
The Case for Confidence Intervals in Controlled Clinical Trials, 411

**STATISTICAL SIGNIFICANCE**  
The Case for Confidence Intervals in Controlled Clinical Trials, 411

**STROKE**  
The Ottawa Stroke Trials Registry Collaborative Group and the Development of the Ottawa Stroke Trials Registry (OSTR),

**SUSPENDED JUDGMENT**  
Assessing Cause and Effect from Trials: A Cautionary Note, 331  
Ignorance and the Process of Learning and Discovery in Medicine, 1  
Reactions to the Motion Picture 'Lorenzo's Oil,' 161  
Seeing Through the Double-Masked Design: A Commentary, 244

**SYMMETRY ASSUMPTION**  
Estimating Sample Sizes for Repeated Measurement Designs, 100

**TRABECULECTOMY**  
The Advanced Glaucoma Intervention Study (AGIS): 1. Study Design and Methods and Baseline Characteristics of Study Patients, 299

**TRAINING LEVELS COMPARISON**  
**TRIAL**  
Design of the Training Levels Comparison Trial, 59

**TRIAL COMPARISON**  
Design of the Training Levels Comparison Trial, 59

**TRIAL ORGANIZATION**  
Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study: Rationale, Design, Organization, and Outcome Definitions, 201

**TUBERCULOSIS**  
Field Trials of Tuberculosis Vaccines: How Could We Have Done Them Better?, 247

**UNCONTROLLED CLINICAL TRIAL**  
Suspended Judgment: Reactions to the Motion Picture 'Lorenzo's Oil,' 161

**VACCINES**  
Field Trials of Tuberculosis Vaccines: How Could We Have Done Them Better?, 247

**VISUAL ACUITY**  
The Advanced Glaucoma Intervention Study (AGIS): 1. Study Design and Methods and Baseline Characteristics of Study Patients, 299

**VISUAL FIELDS**  
The Advanced Glaucoma Intervention Study (AGIS): 1. Study Design and Methods and Baseline Characteristics of Study Patients, 299

**VITAMIN A**  
Data Management for Large Community Trials in Nepal, 220

**WEIGHTED LEAST SQUARES  
ESTIMATOR**  
A Comparison of Two Methods of

Estimating a Common Risk  
Difference in a Stratified Analysis of  
a Multicenter Clinical Trial, 135

